Abstract
Lefl unomide (LEF) is an antirheumatic drug belonging to a class of drugs known as disease modifying antirheumatic drugs, indicated for moderate to severe psoriatic arthritis and rheumatoid arthritis. Orally administrated LEF causes many side eff ects that could result in treatment failure. Hence, in this study, lefl unomide was formulated as a nanoemulsion to develop a transdermal dosage form that can circumvent such side eff ects and increase the rate of successful treatment by improving patient compliance with the medication. The nanoemulsion area was constructed by using pseudo-ternary phase diagrams. A total of 20 nanoemulsion formulas were prepared. These formulas’ mean particle size, zeta potential, and droplet morphology were studied. Thermodynamic stability studies were performed to test the stability of the prepared formulations. Also, the in-vitro release of the drug from the formulations was evaluated using phosphate buff er saline pH 7.4 as the release medium. According to the saturation solubility study results, capryol TM 90 was selected as oil, labrasol and Tween 20 as surfactants for formulation coded A1 and A2, respectively, and transcutol p as cosurfactant together with deionized water as the aqueous phase for the preparation of nanoemulsions. The LEF-nanoemulsion formulations were in the nanosize range (from 54.7–210.2 nm). Images for the chosen formulas revealed dark spherical nanoemulsion droplets against bright surroundings. All of the preparation showed a complete drug release by the end of 220 minutes and the release was highly dependent on the particle size. Based on the result of this study, the prepared LEF-nanoemulsion is successfully prepared and can be considered a promising approach to developing a transdermal preparation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.